Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Ovarian Neoplasms

Free Subscription 03.11.2025 1 Am J Obstet Gynecol 1 BMC Cancer 1 Clin Cancer Res 1 Curr Opin Obstet Gynecol 4 Gynecol Oncol 2 J Clin Oncol 1 Oncology (Williston Park)

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Am J Obstet Gynecol

1. XU X, Long JB, Pollack CE, Desai VB, et al
   Peer Influence on Physicians in Adopting Opportunistic Salpingectomy at the Time of Hysterectomy.
   Am J Obstet Gynecol. 2025 Apr 18:S0002-9378(25)00229.
   PubMed         Abstract available
   
   

   
   BMC Cancer

2. TRAN NL, Wang Y, Quinn KM, Bilandzic M, et al
   Podocalyxin protects high grade serous ovarian cancer spheroids from NK cell infiltration and spheroid destruction.
   BMC Cancer. 2025;25:1674.
   PubMed         Abstract available
   
   

   
   Clin Cancer Res

3. VENEGAS L, Hodgson A, Oza AM
   Biomarkers in High-Grade Serous Ovarian Cancer: Context is everything.
   Clin Cancer Res. 2025 Oct 30. doi: 10.1158/1078-0432.CCR-25-2851.
   PubMed         Abstract available
   
   

   
   Curr Opin Obstet Gynecol

4. BESHAR I, Tostrud LJ, Ghezelayagh T, Blumenthal PD, et al
   Contraception in the setting of gynecologic and breast dysplasia.
   Curr Opin Obstet Gynecol. 2025;37:370-375.
   PubMed         Abstract available
   
   

   
   Gynecol Oncol

5. LINDGREN A, Benseler A, Hogen L, May T, et al
   Description of first recurrence in advanced stage high grade serous ovarian cancer receiving intraperitoneal versus intravenous systemic treatment.
   Gynecol Oncol. 2025;203:90-96.
   PubMed         Abstract available
   
   
6. WANG Y, Li J, Yang Y, Lu X, et al
   Letrozole plus anlotinib as a chemotherapy-free regimen for ER-positive platinum-resistant recurrent epithelial ovarian cancer patients following second-line platinum-based chemotherapy failure: A prospective, single-arm, open-label, phase II study.
   Gynecol Oncol. 2025;203:67-74.
   PubMed         Abstract available
   
   
7. ANDRES S, Tannous A, Kahn RM, Yeoshoua E, et al
   Survival outcomes in patients receiving neoadjuvant chemotherapy for advanced ovarian cancer: Does the indication for neoadjuvant chemotherapy matter?
   Gynecol Oncol. 2025;203:35-42.
   PubMed         Abstract available
   
   
8. MANNING B, Banerjee S, Hawkins TB, Winn-Deen ES, et al
   Extracellular vesicle and particle-based blood test for ovarian cancer screening of average risk population: a promising nested case control study using preclinical samples.
   Gynecol Oncol. 2025;203:26-34.
   PubMed         Abstract available
   
   

   
   J Clin Oncol

9. SHAH M, Fiero MH, Cheng J, Chen TY, et al
   Reply to: Decoding the End Points of Poly (ADP-ribose) Polymerase Inhibitor Trials in Ovarian Cancer.
   J Clin Oncol. 2025 Oct 31:JCO2501933. doi: 10.1200/JCO-25-01933.
   PubMed        
   
   
10. MONK BJ, Coleman RL, O'Malley DM, Moore KN, et al
    Decoding the End Points of Poly (ADP-ribose) Polymerase Inhibitor Trials in Ovarian Cancer.
    J Clin Oncol. 2025 Oct 31:JCO2501721. doi: 10.1200/JCO-25-01721.
    PubMed        
    
    

    
    Oncology (Williston Park)

11. PROSPER AKANKWASA MBBS, Jackson Kakooza Mbbs, Aisha Abdullahi Ahmed Mbbs, Lewis CR, et al
    Late Hepatic Recurrence From Granulosa Cell Tumor: A Case Report.
    Oncology (Williston Park). 2025;39:410-413.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Ovarian Neoplasms is free of charge.